Analystreport

Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating.

Nektar Therapeutics  (NKTR) 
Last nektar therapeutics earnings: 2/27 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nektar.com/investor-relations